Emergent BioSolutions Inc, a life sciences company, focuses on the provision of specialty products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats (PHTs). Its products address PHTs, including chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travelers' diseases; and opioids.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Phone240-631-3200
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$782.40 million
Profitability
Miscellaneous
Employees1,705
Next Earnings Date11/7/2019 (Estimated)
OptionableOptionable
Emergent Biosolutions (NYSE:EBS) Frequently Asked Questions
What is Emergent Biosolutions' stock symbol?
Emergent Biosolutions trades on the New York Stock Exchange (NYSE) under the ticker symbol "EBS."
How will Emergent Biosolutions' stock buyback program work?
Emergent Biosolutions announced that its Board of Directors has authorized a share buyback program on Friday, March 23rd 2018, which allows the company to repurchase $50,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization allows the company to repurchase shares of its stock through open market purchases. Stock repurchase programs are generally an indication that the company's board believes its shares are undervalued.
How were Emergent Biosolutions' earnings last quarter?
Emergent Biosolutions Inc (NYSE:EBS) posted its earnings results on Thursday, August, 1st. The biopharmaceutical company reported $0.12 earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of $0.16 by $0.04. The biopharmaceutical company had revenue of $243.20 million for the quarter, compared to the consensus estimate of $217.94 million. Emergent Biosolutions had a negative net margin of 2.04% and a positive return on equity of 6.68%. The firm's revenue was up 10.4% on a year-over-year basis. During the same period last year, the firm earned $1.07 EPS. View Emergent Biosolutions' Earnings History.
When is Emergent Biosolutions' next earnings date?
What guidance has Emergent Biosolutions issued on next quarter's earnings?
Emergent Biosolutions issued an update on its third quarter 2019 earnings guidance on Thursday, August, 1st. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $245-275 million.
What price target have analysts set for EBS?
8 analysts have issued 12-month price objectives for Emergent Biosolutions' stock. Their forecasts range from $60.00 to $80.00. On average, they anticipate Emergent Biosolutions' stock price to reach $70.25 in the next twelve months. This suggests a possible upside of 37.6% from the stock's current price. View Analyst Price Targets for Emergent Biosolutions.
What is the consensus analysts' recommendation for Emergent Biosolutions?
8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Emergent Biosolutions in the last year. There are currently 1 hold rating and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Emergent Biosolutions.
What are Wall Street analysts saying about Emergent Biosolutions stock?
Here are some recent quotes from research analysts about Emergent Biosolutions stock:
- 1. Cantor Fitzgerald analysts commented, ". Post 1Q19, we reiterate our Overweight rating and our 12- month price target of $75. EBS continues to be the leader in the biodefense field, and the acquisition of Adapt and PaxVax leverage the company’s historical expertise, while further diversifying revenue away from BioThrax. We continue to believe the company’s business is a lot more durable than the Street is giving it credit for, and we expect Emergent to extend a number of its current contracts beyond current estimates, as well as bring some significant pipeline product to market over time. Emergent does not have the risk of commercial insurance reimbursement or payer pricing pressures on the majority of its portfolio." (5/2/2019)
- 2. According to Zacks Investment Research, "Emergent BioSolutions' recent acquisitions of PaxVax and Adapt Pharma have expanded the company’s presence in the public health threats market. Its anthrax vaccine, NuThrax’s regulatory application is under review, with a decision expected in the first half of 2019. We are positive on Emergent’s spin-off of its biosciences business into a separate publicly traded company as it resulted in reduction of the cost structure. Notably, the company derives majority of its revenues from BioThrax sales. Hence, its sole dependence on BioThrax for revenues is a headwind. Moreover, Emergent depends on certain single-source suppliers for key materials and services, which are necessary for manufacturing BioThrax. This, in turn, raises a concern. Shares of the company have underperformed the industry so far this year. Estimates have narrowed ahead of Q1 earnings. Emergent has a mixed record of earnings surprises in the recent quarters." (4/8/2019)
Has Emergent Biosolutions been receiving favorable news coverage?
News stories about EBS stock have trended somewhat negative recently, InfoTrie Sentiment Analysis reports. The research group identifies positive and negative media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Emergent Biosolutions earned a news sentiment score of -1.3 on InfoTrie's scale. They also assigned news stories about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near future. View News Stories for Emergent Biosolutions.
Who are some of Emergent Biosolutions' key competitors?
Some companies that are related to Emergent Biosolutions include Array Biopharma (ARRY), Elanco Animal Health (ELAN), Alnylam Pharmaceuticals (ALNY), Ono Pharmaceutical (OPHLF), Ionis Pharmaceuticals (IONS), GALAPAGOS NV/S (GLPG), SAGE Therapeutics (SAGE), Teva Pharmaceutical Industries (TEVA), Bausch Health Companies (BHC), Catalent (CTLT), Perrigo (PRGO), Jazz Pharmaceuticals (JAZZ), Sarepta Therapeutics (SRPT), Beigene (BGNE) and Dr.Reddy's Laboratories (RDY).
What other stocks do shareholders of Emergent Biosolutions own?
Who are Emergent Biosolutions' key executives?
Emergent Biosolutions' management team includes the folowing people:
- Mr. Fuad El-Hibri, Founder & Exec. Chairman (Age 61)
- Mr. Robert G. Kramer Sr., CEO, Pres & Director (Age 62)
- Mr. Richard S. Lindahl, Exec. VP, CFO & Treasurer (Age 55)
- Mr. Atul Saran, Exec. VP of Corp. Devel., Gen. Counsel & Corp. Sec. (Age 46)
- Mr. Adam R. Havey, Exec. VP of Bus. Operations (Age 48)
Who are Emergent Biosolutions' major shareholders?
Emergent Biosolutions' stock is owned by many different of retail and institutional investors. Top institutional investors include BlackRock Inc. (13.36%), BlackRock Inc. (13.36%), Vanguard Group Inc. (8.93%), Earnest Partners LLC (3.28%), Renaissance Technologies LLC (2.62%) and Rice Hall James & Associates LLC (2.34%). Company insiders that own Emergent Biosolutions stock include Adam Havey, Daniel Abdun-Nabi, Fuad El-Hibri, George A Joulwan, Jerome M Hauer, Kathryn C Zoon, Ronald Richard, Sue Bailey and Zsolt Harsanyi. View Institutional Ownership Trends for Emergent Biosolutions.
Which major investors are selling Emergent Biosolutions stock?
EBS stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Man Group plc, Panagora Asset Management Inc., Acadian Asset Management LLC, Bank of New York Mellon Corp, Sio Capital Management LLC, Royal Bank of Canada and Allianz Asset Management GmbH. Company insiders that have sold Emergent Biosolutions company stock in the last year include Adam Havey, Daniel Abdun-Nabi, Fuad El-Hibri, Kathryn C Zoon and Sue Bailey. View Insider Buying and Selling for Emergent Biosolutions.
Which major investors are buying Emergent Biosolutions stock?
EBS stock was acquired by a variety of institutional investors in the last quarter, including Earnest Partners LLC, Jennison Associates LLC, Jennison Associates LLC, Wells Fargo & Company MN, Morgan Stanley, Nuveen Asset Management LLC, BlackRock Inc. and BlackRock Inc.. View Insider Buying and Selling for Emergent Biosolutions.
How do I buy shares of Emergent Biosolutions?
Shares of EBS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Emergent Biosolutions' stock price today?
One share of EBS stock can currently be purchased for approximately $51.06.
How big of a company is Emergent Biosolutions?
Emergent Biosolutions has a market capitalization of $2.63 billion and generates $782.40 million in revenue each year. The biopharmaceutical company earns $62.70 million in net income (profit) each year or $2.33 on an earnings per share basis. Emergent Biosolutions employs 1,705 workers across the globe.View Additional Information About Emergent Biosolutions.
What is Emergent Biosolutions' official website?
How can I contact Emergent Biosolutions?
Emergent Biosolutions' mailing address is 400 PROFESSIONAL DR SUITE 400, GAITHERSBURG MD, 20879. The biopharmaceutical company can be reached via phone at 240-631-3200 or via email at [email protected]
MarketBeat Community Rating for Emergent Biosolutions (NYSE EBS)
MarketBeat's community ratings are surveys of what our community members think about Emergent Biosolutions and other stocks. Vote "Outperform" if you believe EBS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EBS will underperform the S&P 500 over the long term. You may vote once every thirty days.
